LT3810283T - 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti - Google Patents
3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydytiInfo
- Publication number
- LT3810283T LT3810283T LTEPPCT/US2019/037492T LTUS2019037492T LT3810283T LT 3810283 T LT3810283 T LT 3810283T LT US2019037492 T LTUS2019037492 T LT US2019037492T LT 3810283 T LT3810283 T LT 3810283T
- Authority
- LT
- Lithuania
- Prior art keywords
- difluoropropan
- fluoropropyl
- azetidin
- pyrido
- indol
- Prior art date
Links
- 238000000034 method Methods 0.000 title 2
- GQCXHIKRWBIQMD-AKJBCIBTSA-N 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol Chemical compound FC1=C(C(=CC(=C1)NC1CN(C1)CCCF)F)[C@H]1N([C@@H](CC2=C1NC1=CC=CC=C21)C)CC(CO)(F)F GQCXHIKRWBIQMD-AKJBCIBTSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 150000003892 tartrate salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862687930P | 2018-06-21 | 2018-06-21 | |
| US201862719896P | 2018-08-20 | 2018-08-20 | |
| PCT/US2019/037492 WO2019245974A1 (en) | 2018-06-21 | 2019-06-17 | Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3810283T true LT3810283T (lt) | 2023-08-25 |
Family
ID=67441580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2019/037492T LT3810283T (lt) | 2018-06-21 | 2019-06-17 | 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10954234B2 (lt) |
| EP (2) | EP3810283B1 (lt) |
| JP (4) | JP6916969B1 (lt) |
| KR (2) | KR20230117761A (lt) |
| CN (2) | CN117946107A (lt) |
| AU (3) | AU2019290545B2 (lt) |
| BR (1) | BR112020024073A2 (lt) |
| CA (1) | CA3098203A1 (lt) |
| CL (1) | CL2020003022A1 (lt) |
| CO (1) | CO2020014604A2 (lt) |
| CR (2) | CR20230409A (lt) |
| DK (1) | DK3810283T3 (lt) |
| ES (1) | ES2951829T3 (lt) |
| FI (1) | FI3810283T3 (lt) |
| HR (1) | HRP20230859T1 (lt) |
| HU (1) | HUE064542T2 (lt) |
| IL (1) | IL278063A (lt) |
| LT (1) | LT3810283T (lt) |
| MX (3) | MX2020011531A (lt) |
| PE (1) | PE20211207A1 (lt) |
| PH (1) | PH12020500676A1 (lt) |
| PL (1) | PL3810283T3 (lt) |
| PT (1) | PT3810283T (lt) |
| RS (1) | RS64429B1 (lt) |
| SG (1) | SG11202012171SA (lt) |
| SI (1) | SI3810283T1 (lt) |
| TW (1) | TW202016098A (lt) |
| UA (1) | UA128114C2 (lt) |
| WO (1) | WO2019245974A1 (lt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202012171SA (en) | 2018-06-21 | 2021-01-28 | Hoffmann La Roche | Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use |
| JP2023525022A (ja) * | 2020-05-07 | 2023-06-14 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 組み合わせ |
| US11918561B2 (en) | 2020-05-12 | 2024-03-05 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor |
| CN115836068A (zh) * | 2020-05-15 | 2023-03-21 | 先声药业有限公司 | 吡咯烷类化合物及其应用 |
| EP4174059A1 (en) | 2020-06-28 | 2023-05-03 | Medshine Discovery Inc. | Indazole-fused cyclic compound |
| MX2022015880A (es) * | 2020-06-30 | 2023-02-27 | Genentech Inc | Procesos para elaborar compuestos serd tricíclicos que tienen un resto sustituido de fenilo o piridinilo. |
| WO2022140744A1 (en) * | 2020-12-23 | 2022-06-30 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
| TW202237099A (zh) * | 2021-02-16 | 2022-10-01 | 美商建南德克公司 | 使用包含ｇｄｃ－９５４５及帕他色替之組合療法治療乳癌 |
| JP2024506348A (ja) * | 2021-02-16 | 2024-02-13 | ジェネンテック， インコーポレイテッド | Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療 |
| CN117813288A (zh) | 2021-07-15 | 2024-04-02 | 西藏海思科制药有限公司 | 芳氨基衍生物雌激素受体调节剂及其用途 |
| CN114656444A (zh) * | 2022-03-04 | 2022-06-24 | 河北松辰医药科技有限公司 | 一种2,2-二氟-1,3-丙基磺酸内酯的合成方法 |
| TW202400141A (zh) | 2022-04-28 | 2024-01-01 | 瑞士商赫孚孟拉羅股份公司 | ３－（（１ｒ，３ｒ）－１－（２，６－二氟－４－（（１－（３－氟丙基）四氫吖唉－３－基）胺基）苯基）－３－甲基－１，３，４，９－四氫－２ｈ－吡啶并［３，４－ｂ］吲哚－２－基）－２，２－二氟丙－１－醇酒石酸鹽之固體形式 |
| CN115872996B (zh) * | 2023-02-21 | 2023-05-05 | 山东绿叶制药有限公司 | 一种雌激素受体降解剂化合物及其制备方法和应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7414572L (lt) | 1973-12-06 | 1975-06-09 | Endo Lab | |
| SE455604B (sv) | 1982-06-29 | 1988-07-25 | Stiftelsen Ind Organisk Elektr | Sett att framstella fenetylaminer medelst elektrokemisk reduktion |
| DE3639329C1 (de) | 1986-11-18 | 1988-02-25 | Heesemann Karl Masch | Bandschleifmaschine |
| US5206377A (en) | 1991-12-05 | 1993-04-27 | Whitby Research, Inc. | Compounds useful as antiproliferative agents |
| EP0620222A3 (en) | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
| RU14873U1 (ru) | 2000-06-26 | 2000-09-10 | Закрытое акционерное общество "Патентные услуги" | Комбинированная машина непрерывного литья заготовок |
| EP1347759B1 (en) | 2000-12-08 | 2005-06-29 | Smithkline Beecham Corporation | Antibacterial compounds |
| EP1360185B1 (en) | 2001-02-12 | 2005-08-24 | Lilly Icos LLC | Carboline derivatives |
| US6951961B2 (en) | 2002-05-17 | 2005-10-04 | Marina Nikolaevna Protopopova | Methods of use and compositions for the diagnosis and treatment of infectious disease |
| TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| EP1615698B1 (en) | 2003-04-11 | 2010-09-29 | High Point Pharmaceuticals, LLC | New amide derivatives and pharmaceutical use thereof |
| EP1670314A4 (en) | 2003-09-05 | 2009-02-25 | Sequella Inc | METHODS AND COMPOSITIONS INCLUDE DIAMINE AS A NEW THERAPEUTIC FOR TUBERCULOSIS |
| CN1930162B (zh) | 2004-03-11 | 2010-06-16 | 埃科特莱茵药品有限公司 | 四氢吡啶并吲哚衍生物 |
| US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
| EP1737461B1 (en) | 2004-03-15 | 2012-12-12 | PTC Therapeutics, Inc. | Carboline derivatives useful in the inhibition of angiogenesis |
| US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| EP1786425A1 (en) | 2004-08-02 | 2007-05-23 | SmithKline Beecham Corporation | Useful compounds for hpv infection |
| WO2007002051A1 (en) | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
| EP1968934A4 (en) | 2006-01-02 | 2014-02-26 | Hetero Drugs Ltd | METHOD FOR OBTAINING PURE OSELTAMIVIR |
| AU2008239598A1 (en) | 2007-04-13 | 2008-10-23 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| AU2009242279B2 (en) | 2008-04-29 | 2012-08-30 | Novartis Ag | Spiro-indole derivatives for the treatment of parasitic diseases |
| US9292307B2 (en) | 2008-07-30 | 2016-03-22 | Kyocera Corporation | User interface generation apparatus |
| US20110195929A1 (en) | 2008-08-05 | 2011-08-11 | Summit Corporation Plc | Compounds for the treatment of flaviviral infections |
| US20110237538A1 (en) | 2008-08-06 | 2011-09-29 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| WO2010029313A1 (en) | 2008-09-11 | 2010-03-18 | Summit Corporation Plc. | Antiinfective compounds |
| WO2010049678A2 (en) | 2008-10-31 | 2010-05-06 | Summit Corporation Plc | Treatment of energy utilization diseases |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| WO2010075286A1 (en) | 2008-12-24 | 2010-07-01 | University Of Washington | MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY |
| DE102009006545B4 (de) | 2009-01-29 | 2017-08-17 | Epcos Ag | Überspannungsableiter und Anordnung von mehreren Überspannungsableitern zu einem Array |
| US20120135089A1 (en) | 2009-03-17 | 2012-05-31 | Stockwell Brent R | E3 ligase inhibitors |
| TW201100428A (en) | 2009-03-31 | 2011-01-01 | Arqule Inc | Substituted indolo-piperidine compounds |
| WO2010138695A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| US8703726B2 (en) | 2009-05-27 | 2014-04-22 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
| US20120157402A1 (en) | 2009-05-27 | 2012-06-21 | Liangxian Cao | Methods for treating brain tumors |
| CA2999345A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
| US8697662B2 (en) | 2009-05-27 | 2014-04-15 | Ptc Therapeutics, Inc. | Methods for treating Kaposi sarcoma |
| WO2010138706A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating breast cancer |
| WO2011150162A1 (en) | 2010-05-27 | 2011-12-01 | Ptc Therapeutics, Inc. | Methods for treating viral conditions |
| CN102939287B (zh) | 2010-06-10 | 2016-01-27 | 塞拉根制药公司 | 雌激素受体调节剂及其用途 |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| US9540361B2 (en) | 2010-12-24 | 2017-01-10 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
| US9193714B2 (en) | 2011-12-14 | 2015-11-24 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
| EP2828385B1 (en) | 2012-03-23 | 2018-02-07 | Codexis, Inc. | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs |
| AP2014007906A0 (en) | 2012-03-23 | 2014-08-31 | Novartis Ag | Chemical process for preparing spiroindolones and intermediates thereof |
| EP2682119A1 (en) | 2012-07-03 | 2014-01-08 | Université Libre de Bruxelles | Aromatic N-heterocycle derivatives for use as medicine |
| EP2738173A1 (en) | 2012-11-28 | 2014-06-04 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Heterocyclic compounds as inhibitors of the sodium iodide symporter |
| DK2997033T3 (da) | 2013-05-17 | 2018-01-29 | Merck Sharp & Dohme | Kondenserede tricykliske heterocykliske forbindelser som hiv- integrasehæmmere |
| LT3004090T (lt) | 2013-05-28 | 2018-01-10 | Astrazeneca Ab | Cheminiai junginiai |
| WO2014205138A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
| BR112015030595A2 (pt) | 2013-06-19 | 2017-07-25 | Seragon Pharmaceuticals Inc | moduladores de receptor de estrogênio de azetidina e usos dos mesmos |
| WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| KR102266696B1 (ko) | 2013-10-28 | 2021-06-21 | 드렉셀유니버시티 | 주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제 |
| AU2014358850A1 (en) | 2013-12-06 | 2016-06-16 | F. Hoffmann-La Roche Ag | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
| SG11201607339VA (en) | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Methods and compositions for modulating estrogen receptor mutants |
| WO2015136016A2 (en) | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| CN106536520B (zh) | 2014-06-27 | 2020-08-14 | 诺格拉制药有限公司 | 芳基受体调制剂及其制备和使用方法 |
| US20160175284A1 (en) | 2014-12-18 | 2016-06-23 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| KR20230113416A (ko) * | 2014-12-18 | 2023-07-28 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체조절제 및 이의 용도 |
| US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| KR20180071274A (ko) | 2015-10-01 | 2018-06-27 | 올레마 파마슈티컬스 인코포레이티드 | 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물 |
| CN113788826A (zh) * | 2016-02-01 | 2021-12-14 | 武田药品工业株式会社 | 共晶体 |
| BR112018015419B1 (pt) | 2016-02-05 | 2024-01-30 | Inventisbio Llc | Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica |
| CN109843882A (zh) * | 2016-06-16 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| JP7018026B2 (ja) * | 2016-06-16 | 2022-02-09 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | ヘテロアリールエストロゲン受容体モジュレーター及びその使用 |
| SG11202012171SA (en) | 2018-06-21 | 2021-01-28 | Hoffmann La Roche | Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use |
-
2019
- 2019-06-17 SG SG11202012171SA patent/SG11202012171SA/en unknown
- 2019-06-17 CR CR20230409A patent/CR20230409A/es unknown
- 2019-06-17 SI SI201930592T patent/SI3810283T1/sl unknown
- 2019-06-17 FI FIEP19745335.0T patent/FI3810283T3/fi active
- 2019-06-17 ES ES19745335T patent/ES2951829T3/es active Active
- 2019-06-17 BR BR112020024073-7A patent/BR112020024073A2/pt unknown
- 2019-06-17 HR HRP20230859TT patent/HRP20230859T1/hr unknown
- 2019-06-17 CR CR20200621A patent/CR20200621A/es unknown
- 2019-06-17 DK DK19745335.0T patent/DK3810283T3/da active
- 2019-06-17 KR KR1020237026161A patent/KR20230117761A/ko active IP Right Grant
- 2019-06-17 KR KR1020217001924A patent/KR102564647B1/ko active IP Right Grant
- 2019-06-17 PE PE2020001888A patent/PE20211207A1/es unknown
- 2019-06-17 US US16/443,515 patent/US10954234B2/en active Active
- 2019-06-17 CA CA3098203A patent/CA3098203A1/en active Pending
- 2019-06-17 EP EP19745335.0A patent/EP3810283B1/en active Active
- 2019-06-17 LT LTEPPCT/US2019/037492T patent/LT3810283T/lt unknown
- 2019-06-17 TW TW108120952A patent/TW202016098A/zh unknown
- 2019-06-17 HU HUE19745335A patent/HUE064542T2/hu unknown
- 2019-06-17 CN CN202410165649.2A patent/CN117946107A/zh active Pending
- 2019-06-17 AU AU2019290545A patent/AU2019290545B2/en active Active
- 2019-06-17 WO PCT/US2019/037492 patent/WO2019245974A1/en active Application Filing
- 2019-06-17 PL PL19745335.0T patent/PL3810283T3/pl unknown
- 2019-06-17 EP EP23178559.3A patent/EP4295845A3/en active Pending
- 2019-06-17 PT PT197453350T patent/PT3810283T/pt unknown
- 2019-06-17 MX MX2020011531A patent/MX2020011531A/es unknown
- 2019-06-17 RS RS20230634A patent/RS64429B1/sr unknown
- 2019-06-17 UA UAA202100182A patent/UA128114C2/uk unknown
- 2019-06-17 JP JP2020570698A patent/JP6916969B1/ja active Active
- 2019-06-17 CN CN201980041221.4A patent/CN112437685A/zh active Pending
-
2020
- 2020-10-15 IL IL278063A patent/IL278063A/en unknown
- 2020-10-29 MX MX2022016065A patent/MX2022016065A/es unknown
- 2020-10-29 MX MX2023006785A patent/MX2023006785A/es unknown
- 2020-11-20 CL CL2020003022A patent/CL2020003022A1/es unknown
- 2020-11-25 CO CONC2020/0014604A patent/CO2020014604A2/es unknown
- 2020-12-03 US US17/110,607 patent/US11780834B2/en active Active
- 2020-12-17 PH PH12020500676A patent/PH12020500676A1/en unknown
-
2021
- 2021-07-16 JP JP2021117638A patent/JP2021191751A/ja active Pending
- 2021-07-16 JP JP2021117633A patent/JP2021191750A/ja active Pending
-
2022
- 2022-05-03 AU AU2022202967A patent/AU2022202967B2/en active Active
-
2023
- 2023-09-13 AU AU2023229513A patent/AU2023229513A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002374A patent/JP2024054111A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE064542T2 (hu) | A 3-((1R,3R)1(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9 -tetrahidro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropán-1-ol tartarátsó szilárd formái, eljárás elõállításukra és rákos megbetegedések kezelésében történõ alkalmazási módszereik | |
| SG11202109020QA (en) | N-substituted indoles and other heterocycles for treating brain disorders | |
| JOP20200001A1 (ar) | كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم | |
| EP2532657A3 (en) | Compounds and methods of use | |
| NO20100077L (no) | Behandling med alfa7-selektive ligander | |
| GB201212081D0 (en) | New polymorph | |
| HUE055339T2 (hu) | Új L-triptofán-exportfehérje és eljárás L-triptofán elõállítására annak alkalmazásával | |
| MX354373B (es) | Proceso para hacer compuestos de ciclopentapirimidina hidroxilada y sus sales. | |
| CA3040011C (en) | Methods for treating filled microporous membranes | |
| EA201401027A1 (ru) | НОВЫЕ КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ ГЕМИНАПАДИЗИЛАТА 5-(2-{[6-(2,2-ДИФТОР-2-ФЕНИЛЭТОКСИ)ГЕКСИЛ]АМИНО}-1-(R)-ГИДРОКСИЭТИЛ)-8-ГИДРОКСИХИНОЛИН-2(1H)-ОНА В КАЧЕСТВЕ АГОНИСТОВ βАДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| IL281025A (en) | Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-inol)-pyrrolidine-2-YL]imidazo[1,5-A]-pyrazine-1-YL}N- (pyridine-2-YL)-benzamide | |
| ZA202003984B (en) | High-frequency somatic embryo regeneration growth medium without germplasm genotype restriction and application thereof | |
| MX2020006026A (es) | Sal de fumarato de (r)-3-(1-(2,3-dicloro-4-(pirazin-2-il)fenil)-2, 2,2-trifluoroetil)-1-metil-1-(1-metilpiperidin-4-il)urea, metodos de preparacion y sus usos. | |
| IL289198A (en) | Solid forms of tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-5,2-diazaspiro[4.3]octane- 5-carboxylate and methods for their preparation | |
| HUE058049T2 (hu) | Eljárás N-((1R,2S,SR)-5-(terc-butilamino)-2-((S)-3-(7-terc-butilpirazolo[1,5-A][1,3,5] triazin-4-ilamino)-2-oxopirrolidin-1-il)ciklohexil)acetamid elõállítására | |
| AR114974A1 (es) | Procesos para preparar compuestos tricíclicos fusionados que comprenden un resto piridinilo o fenilo sustituido, incluidos métodos para su uso | |
| SI2171115T1 (sl) | Postopek toplotne obdelave glav valjev, izdelanih iz zlitine na osnovi aluminija, in glave valjev, ki imajo izboljšane lastnosti trajne trdnosti | |
| WO2017214249A3 (en) | Gm-csf variants and methods of use | |
| NZ577546A (en) | Aminoguanidines as melanocortin receptor ligands useful for the treatment of inflammation and autoimmunie disorders | |
| IL308121A (en) | Treatment methods with n-((r)-1-(3-chloropyridin-2-yl)-2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1 - oxoisoindoline-5-carboxamide | |
| WO2020159041A9 (ko) | 미립자 공정을 통해 분산된 파우더 조성물의 제조방법 및 이를 통해 제조된 파우더 조성물 | |
| WO2016164476A3 (en) | Combination of an acat1 inhibitor and a cyp1 1 b1 inhibitor for treating disorders associated with excess cortisol production | |
| EP4054333A4 (en) | ANODIZED BIOCIDAL METAL MATERIAL, METHOD FOR MANUFACTURING THE MATERIAL AND METHOD FOR REACTIVATING THE MATERIAL | |
| EP3922728A4 (en) | PROCESS FOR THE PREPARATION OF (1R ,3R)-3-(TRIFLUORMETHYL)CYCLOHEXAN-1-OL AND INTERMEDIATE THEREOF | |
| GB201808159D0 (en) | Therapeutic compositions for treating neurocognative, neurodevelopmental and psychocognitive disorders |